BioAtla (NASDAQ:BCAB – Get Free Report) issued its earnings results on Monday. The company reported ($4.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.00) by $2.26, FiscalAI reports. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $5.59 million.
BioAtla Price Performance
Shares of NASDAQ BCAB opened at $1.56 on Monday. BioAtla has a 1-year low of $1.07 and a 1-year high of $71.50. The business’s 50 day moving average is $1.61 and its two-hundred day moving average is $4.46. The stock has a market capitalization of $2.60 million, a P/E ratio of -0.06 and a beta of 0.53.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a report on Monday, August 31st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioAtla currently has an average rating of “Hold” and an average target price of $200.00.
View Our Latest Analysis on BioAtla
About BioAtla
BioAtla, Inc. was a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company used its Conditionally Active Biologics (CAB) platform to design antibody-based medicines intended to become active primarily within the tumor microenvironment, with the goal of improving treatment effectiveness while limiting effects on healthy tissue. BioAtla’s investigational pipeline included antibody-drug conjugates and immune-modulating therapies. Its lead programs included mecbotamab vedotin, an antibody-drug conjugate designed to target AXL, and ozuriftamab vedotin, an investigational therapy directed at ROR2.
Read More
- Five stocks we like better than BioAtla
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
